Plus Therapeutics, Inc. (PSTV) 10-Year Financial Performance & Capital Metrics

PSTV • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Show more

Revenue $6M +18.5%
EBITDA -$14M -9.1%
Net Income -$13M +2.5%
EPS (Diluted) -2.34 +44.8%
Gross Margin 85.37% +187.8%
EBITDA Margin -237.69% +8.0%
Operating Margin -252.32% +6.9%
Net Margin -222.84% +17.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -3.95 +88.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-2.62%

5Y-3.61%

3Y-

TTM-8.16%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.33%

ROCE

10Y Avg-113.68%

5Y Avg-158.26%

3Y Avg-175.17%

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.66M	11.38M	6.41M	2.98M	7M	303K	0	224K	4.91M	5.82M
Revenue Growth %	0.53%	-0.02%	-0.44%	-0.53%	1.35%	-0.96%	-1%	-	20.93%	0.19%
Cost of Goods Sold+	3.19M	2.71M	1.32M	1.15M	0	2.7M	66K	712K	9.69M	852K
COGS % of Revenue	0.27%	0.24%	0.21%	0.38%	-	8.91%	-	3.18%	1.97%	0.15%
Gross Profit+	8.47M	8.66M	5.09M	1.83M	7M	-2.4M	-66K	-488K	-4.78M	4.97M
Gross Margin %	0.73%	0.76%	0.79%	0.62%	1%	-7.91%	-	-2.18%	-0.97%	0.85%
Gross Profit Growth %	0.82%	0.02%	-0.41%	-0.64%	2.81%	-1.34%	0.97%	-6.39%	-8.79%	2.04%
Operating Expenses+	31.43M	28.37M	25.78M	10.77M	10.65M	7.19M	12.43M	19.22M	8.54M	19.67M
OpEx % of Revenue	2.7%	2.49%	4.02%	3.61%	1.52%	23.72%	-	85.82%	1.74%	3.38%
Selling, General & Admin	12.43M	12.17M	11.19M	6.22M	5.29M	6.41M	6.85M	9.53M	8.54M	9.94M
SG&A % of Revenue	1.07%	1.07%	1.74%	2.09%	0.76%	21.14%	-	42.53%	1.74%	1.71%
Research & Development	19M	16.2M	13.36M	5.52M	5.37M	3.48M	5.32M	9.7M	9.69M	10.58M
R&D % of Revenue	1.63%	1.42%	2.08%	1.85%	0.77%	11.49%	-	43.29%	1.97%	1.82%
Other Operating Expenses	-7.67M	0	1.23M	-1.15M	0	-2.7M	250K	0	-9.69M	-852K
Operating Income+	-15.29M	-19.71M	-20.68M	-8.76M	-3.66M	-9.58M	-12.49M	-19.71M	-13.32M	-14.7M
Operating Margin %	-1.31%	-1.73%	-3.23%	-2.94%	-0.52%	-31.63%	-	-88%	-2.71%	-2.52%
Operating Income Growth %	0.53%	-0.29%	-0.05%	0.58%	0.58%	-1.62%	-0.3%	-0.58%	0.32%	-0.1%
EBITDA+	-14.19M	-18.52M	-18.53M	-6.76M	-2.76M	-9.22M	-12.07M	-19M	-12.69M	-13.84M
EBITDA Margin %	-1.22%	-1.63%	-2.89%	-2.27%	-0.39%	-30.42%	-	-84.82%	-2.58%	-2.38%
EBITDA Growth %	0.55%	-0.31%	-0%	0.64%	0.59%	-2.34%	-0.31%	-0.57%	0.33%	-0.09%
D&A (Non-Cash Add-back)	1.09M	1.18M	2.15M	2M	896K	366K	419K	712K	628K	852K
EBIT	-15.37M	-19.45M	-20.64M	-6.96M	-1.43M	-8.8M	-12.47M	-19.56M	-13.32M	-9.25M
Net Interest Income+	-3.37M	-2.57M	-2.02M	-1.88M	-1.8M	-1.06M	-913K	-564K	5K	-3.45M
Interest Income	9K	19K	33K	43K	55K	50K	19K	147K	400K	273K
Interest Expense	3.38M	2.59M	2.05M	1.92M	1.85M	1.11M	932K	711K	395K	3.72M
Other Income/Expense	-3.46M	-2.34M	-2M	-116K	374K	1.34M	-907K	-563K	5K	1.72M
Pretax Income+	-18.74M	-22.05M	-22.69M	-8.88M	-3.28M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Pretax Margin %	-1.61%	-1.94%	-3.54%	-2.98%	-0.47%	-27.2%	-	-90.51%	-2.71%	-2.23%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1.42%	3.32%	1%	1%	1%	1%	1%
Net Income+	-18.74M	-22.05M	-22.69M	-12.63M	-10.89M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Net Margin %	-1.61%	-1.94%	-3.54%	-4.24%	-1.56%	-27.2%	-	-90.51%	-2.71%	-2.23%
Net Income Growth %	0.5%	-0.18%	-0.03%	0.44%	0.14%	0.24%	-0.63%	-0.51%	0.34%	0.03%
Net Income (Continuing)	-18.74M	-22.05M	-22.69M	-8.88M	-3.28M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Discontinued Operations	0	0	0	-3.76M	-7.6M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14995.94	-9600.00	-5253.82	-1304.70	-138.10	-27.90	-17.78	-11.55	-4.24	-2.34
EPS Growth %	0.63%	0.36%	0.45%	0.75%	0.89%	0.8%	0.36%	0.35%	0.63%	0.45%
EPS (Basic)	-14995.94	-9600.00	-5253.82	-1304.70	-124.05	-27.90	-17.78	-11.55	-4.24	-1.95
Diluted Shares Outstanding	140.8M	17.29M	432	11.59K	92.27K	295.19K	805.95K	1.75M	3.14M	7.7M
Basic Shares Outstanding	140.8M	17.29M	432	11.59K	92.27K	295.19K	804.74K	1.75M	3.14M	6.64M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.24M	18.75M	14.86M	9.65M	19.82M	9.18M	19.72M	21.82M	9.83M	5.26M
Cash & Short-Term Investments	14.34M	12.56M	9.55M	5.26M	17.55M	8.35M	18.4M	18.12M	8.55M	3.61M
Cash Only	14.34M	12.56M	9.55M	5.26M	17.55M	8.35M	18.4M	18.12M	8.55M	76K
Short-Term Investments	0	0	0	0	0	0	0	0	0	3.53M
Accounts Receivable	1.31M	1.29M	257K	233K	1.31M	59K	7K	0	0	571K
Days Sales Outstanding	41.07	41.47	14.63	28.51	68.48	71.07	-	-	-	35.79
Inventory	4.3M	3.73M	3.18M	107K	107K	0	0	0	0	0
Days Inventory Outstanding	492.39	500.78	881.48	34.02	-	-	-	-	-	-
Other Current Assets	0	350K	675K	3.32M	40K	0	0	0	0	1.08M
Total Non-Current Assets+	16.45M	15.86M	16.75M	14.34M	3.4M	2.93M	2.26M	2.05M	1.55M	1.37M
Property, Plant & Equipment	1.63M	1.16M	3.05M	2.3M	2.96M	2.46M	1.82M	1.57M	1.11M	521K
Fixed Asset Turnover	7.15x	9.84x	2.10x	1.30x	2.36x	0.12x	-	0.14x	4.43x	11.18x
Goodwill	3.92M	3.92M	3.92M	372K	372K	372K	372K	372K	372K	372K
Intangible Assets	9.03M	8.45M	7.21M	0	0	86K	51K	94K	42K	469K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.87M	2.34M	2.57M	11.67M	72K	16K	16K	12K	32K	12K
Total Assets+	37.7M	34.61M	31.61M	23.99M	23.23M	12.11M	21.98M	23.87M	11.39M	6.63M
Asset Turnover	0.31x	0.33x	0.20x	0.12x	0.30x	0.03x	-	0.01x	0.43x	0.88x
Asset Growth %	-0.03%	-0.08%	-0.09%	-0.24%	-0.03%	-0.48%	0.82%	0.09%	-0.52%	-0.42%
Total Current Liabilities+	8.44M	12.5M	18.41M	17.56M	14.49M	8.54M	5.87M	11.85M	10.73M	15.55M
Accounts Payable	1.01M	1.33M	1.3M	721K	327K	789K	2.61M	8.36M	4.76M	9.47M
Days Payables Outstanding	115.59	179.07	359.18	229.24	-	106.66	14.44K	4.29K	179.22	4.06K
Short-Term Debt	0	6.63M	13.62M	14.2M	11.06M	6.33M	1.61M	1.72M	3.98M	3.29M
Deferred Revenue (Current)	221K	215K	0	0	0	0	0	0	0	0
Other Current Liabilities	5.58M	2.83M	225K	973K	1.99M	299K	374K	346K	370K	2.74M
Current Ratio	2.52x	1.50x	0.81x	0.55x	1.37x	1.07x	3.36x	1.84x	0.92x	0.34x
Quick Ratio	2.01x	1.20x	0.63x	0.54x	1.36x	1.07x	3.36x	1.84x	0.92x	0.34x
Cash Conversion Cycle	417.87	363.18	536.93	-166.71	-	-	-	-	-	-
Total Non-Current Liabilities+	17.05M	11.12M	201K	1.21M	7.58M	535K	5.28M	5.57M	2.01M	31K
Long-Term Debt	16.68M	11.01M	0	0	0	0	5M	3.79M	0	0
Capital Lease Obligations	0	0	0	0	646K	528K	269K	141K	85K	31K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	374K	17K	107K	1.04M	6.94M	7K	1K	1.64M	1.92M	0
Total Liabilities	25.49M	23.62M	18.61M	18.77M	22.07M	9.07M	11.14M	17.42M	12.74M	15.58M
Total Debt+	16.68M	17.64M	13.62M	14.2M	11.97M	7M	6.99M	5.75M	4.18M	3.37M
Net Debt	2.34M	5.08M	4.07M	8.94M	-5.58M	-1.35M	-11.41M	-12.37M	-4.37M	3.29M
Debt / Equity	1.37x	1.61x	1.05x	2.72x	10.32x	2.31x	0.65x	0.89x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-4.52x	-7.60x	-10.09x	-4.56x	-1.97x	-8.66x	-13.40x	-27.72x	-33.72x	-3.95x
Total Equity+	12.21M	10.99M	13M	5.22M	1.16M	3.03M	10.84M	6.45M	-1.35M	-8.95M
Equity Growth %	3.14%	-0.1%	0.18%	-0.6%	-0.78%	1.61%	2.58%	-0.41%	-1.21%	-5.64%
Book Value per Share	0.09	0.64	30102.04	450.82	12.57	10.27	13.45	3.68	-0.43	-1.16
Total Shareholders' Equity	12.21M	10.99M	13M	5.22M	1.16M	3.03M	10.84M	6.45M	-1.35M	-8.95M
Common Stock	13K	22K	6K	0	4K	7K	16K	34K	5K	6K
Retained Earnings	-357.02M	-379.06M	-401.75M	-414.38M	-425.27M	-433.51M	-446.91M	-467.19M	-480.5M	-493.48M
Treasury Stock	0	0	0	0	0	0	0	0	-126K	-500K
Accumulated OCI	996K	1.26M	1.39M	1.22M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.47M	-19.53M	-18.13M	-11.97M	-5.91M	-8.43M	-10.28M	-12.97M	-12.85M	-10.55M
Operating CF Margin %	-1.76%	-1.72%	-2.83%	-4.01%	-0.84%	-27.83%	-	-57.91%	-2.62%	-1.81%
Operating CF Growth %	0.33%	0.05%	0.07%	0.34%	0.51%	-0.43%	-0.22%	-0.26%	0.01%	0.18%
Net Income	-18.74M	-22.05M	-22.69M	-12.63M	-10.89M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Depreciation & Amortization	1.09M	1.18M	2.15M	2M	896K	366K	395K	619K	628K	723K
Stock-Based Compensation	2.04M	1.08M	753K	355K	127K	247K	606K	606K	569K	550K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-6.16M	1.02M	2.69M	-668K	4.9M	-925K	880K	481K	384K	-2.07M
Working Capital Changes	1.3M	-772K	-1.04M	-1.03M	-938K	119K	1.24M	5.6M	-1.12M	3.22M
Change in Receivables	328K	-179K	1.13M	-173K	-1.2M	1.17M	0	0	0	-571K
Change in Inventory	490K	471K	251K	475K	259K	0	0	0	0	0
Change in Payables	771K	-673K	-1.82M	-1.42M	-23K	-1.23M	1.73M	0	-3.68M	4.7M
Cash from Investing+	-613K	64K	-1.38M	-133K	5.57M	-493K	-82K	-759K	-160K	-4.11M
Capital Expenditures	-611K	-67K	-1.5M	-133K	-67K	-93K	-144K	-509K	-160K	-146K
CapEx % of Revenue	0.05%	0.01%	0.23%	0.04%	0.01%	0.31%	-	2.27%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2K	131K	113K	0	0	-400K	62K	-250K	0	-545K
Cash from Financing+	20.8M	17.61M	16.82M	7.17M	12.63M	-319K	20.42M	13.45M	3.44M	6.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-75K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-850K	-3.86M	0	-66K	490K	1.1M	2.02M	-773K	-348K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.09M	-19.6M	-19.62M	-12.11M	-5.97M	-8.93M	-10.42M	-13.73M	-13.01M	-10.7M
FCF Margin %	-1.81%	-1.72%	-3.06%	-4.06%	-0.85%	-29.46%	-	-61.3%	-2.65%	-1.84%
FCF Growth %	0.33%	0.07%	-0%	0.38%	0.51%	-0.49%	-0.17%	-0.32%	0.05%	0.18%
FCF per Share	-0.15	-1.13	-45440.19	-1044.69	-64.74	-30.24	-12.93	-7.84	-4.14	-1.39
FCF Conversion (FCF/Net Income)	1.09x	0.89x	0.80x	0.95x	0.54x	1.02x	0.77x	0.64x	0.97x	0.81x
Interest Paid	0	0	0	0	0	0	0	327K	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-576.38%	-190.12%	-189.16%	-138.64%	-341.02%	-393.27%	-193.25%	-234.65%	-522.5%	-
Return on Invested Capital (ROIC)	-116.81%	-96.56%	-93.63%	-42.07%	-56.28%	-	-1688.11%	-	-	-
Gross Margin	72.67%	76.14%	79.44%	61.52%	100%	-791.09%	-	-217.86%	-97.23%	85.37%
Net Margin	-160.77%	-193.73%	-353.86%	-423.53%	-155.57%	-2719.8%	-	-9051.34%	-271.04%	-222.84%
Debt / Equity	1.37x	1.61x	1.05x	2.72x	10.32x	2.31x	0.65x	0.89x	-	-
Interest Coverage	-4.52x	-7.60x	-10.09x	-4.56x	-1.97x	-8.66x	-13.40x	-27.72x	-33.72x	-3.95x
FCF Conversion	1.09x	0.89x	0.80x	0.95x	0.54x	1.02x	0.77x	0.64x	0.97x	0.81x
Revenue Growth	53.45%	-2.39%	-43.66%	-53.47%	134.6%	-95.67%	-100%	-	2093.3%	18.54%

Revenue by Segment

	2012	2013	2014	2015	2016	2017	2018	2019	2022
Grant	-	-	-	-	-	-	-	-	224K
Grant Growth	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	-	2.67M	901K	-
Product Growth	-	-	-	-	-	-	-	-66.27%	-
Consumable	-	-	-	-	-	-	2.17M	-	-
Consumable Growth	-	-	-	-	-	-	-	-	-
Other Products	-	-	-	-	-	-	277K	-	-
Other Products Growth	-	-	-	-	-	-	-	-	-
Device	-	-	-	-	-	-	225K	-	-
Device Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2012	2013	2014	2015	2016	2017	2018	2019	2022
JAPAN	-	-	-	2.39M	3.28M	1.92M	2.06M	-	-
JAPAN Growth	-	-	-	-	36.97%	-41.32%	6.96%	-	-
Americas	-	-	-	-	936K	345K	293K	-	-
Americas Growth	-	-	-	-	-	-63.14%	-15.07%	-	-
E M E A	-	-	-	-	379K	344K	270K	-	-
E M E A Growth	-	-	-	-	-	-9.23%	-21.51%	-	-
Asia Pacific	-	-	-	787K	62K	76K	50K	-	-
Asia Pacific Growth	-	-	-	-	-92.12%	22.58%	-34.21%	-	-
America	-	-	-	982K	-	-	-	-	-
America Growth	-	-	-	-	-	-	-	-	-
Europe	2M	1.24M	506K	675K	-	-	-	-	-
Europe Growth	-	-38.12%	-59.19%	33.40%	-	-	-	-	-
Japan	-	-	3.07M	-	-	-	-	-	-
Japan Growth	-	-	-	-	-	-	-	-	-
North America	1.14M	1.08M	894K	-	-	-	-	-	-
North America Growth	-	-5.60%	-17.15%	-	-	-	-	-	-
Other countries	1.21M	2.69M	485K	-	-	-	-	-	-
Other countries Growth	-	122.64%	-82.00%	-	-	-	-	-	-
Japan segment	4.35M	2.11M	-	-	-	-	-	-	-
Japan segment Growth	-	-51.54%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Plus Therapeutics, Inc. (PSTV) reported $5.3M in revenue for fiscal year 2024. This represents a 47% decrease from $10.0M in 2011.

Plus Therapeutics, Inc. (PSTV) grew revenue by 18.5% over the past year. This is strong growth.

Plus Therapeutics, Inc. (PSTV) reported a net loss of $20.6M for fiscal year 2024.

Dividend & Returns

Plus Therapeutics, Inc. (PSTV) had negative free cash flow of $15.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Plus Therapeutics, Inc. (PSTV) 10-Year Financial Performance & Capital Metrics

PSTV • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $6M +18.5%
EBITDA -$14M -9.1%
Net Income -$13M +2.5%
EPS (Diluted) -2.34 +44.8%
Gross Margin 85.37% +187.8%
EBITDA Margin -237.69% +8.0%
Operating Margin -252.32% +6.9%
Net Margin -222.84% +17.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -3.95 +88.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-2.62%

5Y-3.61%

3Y-

TTM-8.16%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.33%

ROCE

10Y Avg-113.68%

5Y Avg-158.26%

3Y Avg-175.17%

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.66M	11.38M	6.41M	2.98M	7M	303K	0	224K	4.91M	5.82M
Revenue Growth %	0.53%	-0.02%	-0.44%	-0.53%	1.35%	-0.96%	-1%	-	20.93%	0.19%
Cost of Goods Sold+	3.19M	2.71M	1.32M	1.15M	0	2.7M	66K	712K	9.69M	852K
COGS % of Revenue	0.27%	0.24%	0.21%	0.38%	-	8.91%	-	3.18%	1.97%	0.15%
Gross Profit+	8.47M	8.66M	5.09M	1.83M	7M	-2.4M	-66K	-488K	-4.78M	4.97M
Gross Margin %	0.73%	0.76%	0.79%	0.62%	1%	-7.91%	-	-2.18%	-0.97%	0.85%
Gross Profit Growth %	0.82%	0.02%	-0.41%	-0.64%	2.81%	-1.34%	0.97%	-6.39%	-8.79%	2.04%
Operating Expenses+	31.43M	28.37M	25.78M	10.77M	10.65M	7.19M	12.43M	19.22M	8.54M	19.67M
OpEx % of Revenue	2.7%	2.49%	4.02%	3.61%	1.52%	23.72%	-	85.82%	1.74%	3.38%
Selling, General & Admin	12.43M	12.17M	11.19M	6.22M	5.29M	6.41M	6.85M	9.53M	8.54M	9.94M
SG&A % of Revenue	1.07%	1.07%	1.74%	2.09%	0.76%	21.14%	-	42.53%	1.74%	1.71%
Research & Development	19M	16.2M	13.36M	5.52M	5.37M	3.48M	5.32M	9.7M	9.69M	10.58M
R&D % of Revenue	1.63%	1.42%	2.08%	1.85%	0.77%	11.49%	-	43.29%	1.97%	1.82%
Other Operating Expenses	-7.67M	0	1.23M	-1.15M	0	-2.7M	250K	0	-9.69M	-852K
Operating Income+	-15.29M	-19.71M	-20.68M	-8.76M	-3.66M	-9.58M	-12.49M	-19.71M	-13.32M	-14.7M
Operating Margin %	-1.31%	-1.73%	-3.23%	-2.94%	-0.52%	-31.63%	-	-88%	-2.71%	-2.52%
Operating Income Growth %	0.53%	-0.29%	-0.05%	0.58%	0.58%	-1.62%	-0.3%	-0.58%	0.32%	-0.1%
EBITDA+	-14.19M	-18.52M	-18.53M	-6.76M	-2.76M	-9.22M	-12.07M	-19M	-12.69M	-13.84M
EBITDA Margin %	-1.22%	-1.63%	-2.89%	-2.27%	-0.39%	-30.42%	-	-84.82%	-2.58%	-2.38%
EBITDA Growth %	0.55%	-0.31%	-0%	0.64%	0.59%	-2.34%	-0.31%	-0.57%	0.33%	-0.09%
D&A (Non-Cash Add-back)	1.09M	1.18M	2.15M	2M	896K	366K	419K	712K	628K	852K
EBIT	-15.37M	-19.45M	-20.64M	-6.96M	-1.43M	-8.8M	-12.47M	-19.56M	-13.32M	-9.25M
Net Interest Income+	-3.37M	-2.57M	-2.02M	-1.88M	-1.8M	-1.06M	-913K	-564K	5K	-3.45M
Interest Income	9K	19K	33K	43K	55K	50K	19K	147K	400K	273K
Interest Expense	3.38M	2.59M	2.05M	1.92M	1.85M	1.11M	932K	711K	395K	3.72M
Other Income/Expense	-3.46M	-2.34M	-2M	-116K	374K	1.34M	-907K	-563K	5K	1.72M
Pretax Income+	-18.74M	-22.05M	-22.69M	-8.88M	-3.28M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Pretax Margin %	-1.61%	-1.94%	-3.54%	-2.98%	-0.47%	-27.2%	-	-90.51%	-2.71%	-2.23%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1.42%	3.32%	1%	1%	1%	1%	1%
Net Income+	-18.74M	-22.05M	-22.69M	-12.63M	-10.89M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Net Margin %	-1.61%	-1.94%	-3.54%	-4.24%	-1.56%	-27.2%	-	-90.51%	-2.71%	-2.23%
Net Income Growth %	0.5%	-0.18%	-0.03%	0.44%	0.14%	0.24%	-0.63%	-0.51%	0.34%	0.03%
Net Income (Continuing)	-18.74M	-22.05M	-22.69M	-8.88M	-3.28M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Discontinued Operations	0	0	0	-3.76M	-7.6M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14995.94	-9600.00	-5253.82	-1304.70	-138.10	-27.90	-17.78	-11.55	-4.24	-2.34
EPS Growth %	0.63%	0.36%	0.45%	0.75%	0.89%	0.8%	0.36%	0.35%	0.63%	0.45%
EPS (Basic)	-14995.94	-9600.00	-5253.82	-1304.70	-124.05	-27.90	-17.78	-11.55	-4.24	-1.95
Diluted Shares Outstanding	140.8M	17.29M	432	11.59K	92.27K	295.19K	805.95K	1.75M	3.14M	7.7M
Basic Shares Outstanding	140.8M	17.29M	432	11.59K	92.27K	295.19K	804.74K	1.75M	3.14M	6.64M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.24M	18.75M	14.86M	9.65M	19.82M	9.18M	19.72M	21.82M	9.83M	5.26M
Cash & Short-Term Investments	14.34M	12.56M	9.55M	5.26M	17.55M	8.35M	18.4M	18.12M	8.55M	3.61M
Cash Only	14.34M	12.56M	9.55M	5.26M	17.55M	8.35M	18.4M	18.12M	8.55M	76K
Short-Term Investments	0	0	0	0	0	0	0	0	0	3.53M
Accounts Receivable	1.31M	1.29M	257K	233K	1.31M	59K	7K	0	0	571K
Days Sales Outstanding	41.07	41.47	14.63	28.51	68.48	71.07	-	-	-	35.79
Inventory	4.3M	3.73M	3.18M	107K	107K	0	0	0	0	0
Days Inventory Outstanding	492.39	500.78	881.48	34.02	-	-	-	-	-	-
Other Current Assets	0	350K	675K	3.32M	40K	0	0	0	0	1.08M
Total Non-Current Assets+	16.45M	15.86M	16.75M	14.34M	3.4M	2.93M	2.26M	2.05M	1.55M	1.37M
Property, Plant & Equipment	1.63M	1.16M	3.05M	2.3M	2.96M	2.46M	1.82M	1.57M	1.11M	521K
Fixed Asset Turnover	7.15x	9.84x	2.10x	1.30x	2.36x	0.12x	-	0.14x	4.43x	11.18x
Goodwill	3.92M	3.92M	3.92M	372K	372K	372K	372K	372K	372K	372K
Intangible Assets	9.03M	8.45M	7.21M	0	0	86K	51K	94K	42K	469K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.87M	2.34M	2.57M	11.67M	72K	16K	16K	12K	32K	12K
Total Assets+	37.7M	34.61M	31.61M	23.99M	23.23M	12.11M	21.98M	23.87M	11.39M	6.63M
Asset Turnover	0.31x	0.33x	0.20x	0.12x	0.30x	0.03x	-	0.01x	0.43x	0.88x
Asset Growth %	-0.03%	-0.08%	-0.09%	-0.24%	-0.03%	-0.48%	0.82%	0.09%	-0.52%	-0.42%
Total Current Liabilities+	8.44M	12.5M	18.41M	17.56M	14.49M	8.54M	5.87M	11.85M	10.73M	15.55M
Accounts Payable	1.01M	1.33M	1.3M	721K	327K	789K	2.61M	8.36M	4.76M	9.47M
Days Payables Outstanding	115.59	179.07	359.18	229.24	-	106.66	14.44K	4.29K	179.22	4.06K
Short-Term Debt	0	6.63M	13.62M	14.2M	11.06M	6.33M	1.61M	1.72M	3.98M	3.29M
Deferred Revenue (Current)	221K	215K	0	0	0	0	0	0	0	0
Other Current Liabilities	5.58M	2.83M	225K	973K	1.99M	299K	374K	346K	370K	2.74M
Current Ratio	2.52x	1.50x	0.81x	0.55x	1.37x	1.07x	3.36x	1.84x	0.92x	0.34x
Quick Ratio	2.01x	1.20x	0.63x	0.54x	1.36x	1.07x	3.36x	1.84x	0.92x	0.34x
Cash Conversion Cycle	417.87	363.18	536.93	-166.71	-	-	-	-	-	-
Total Non-Current Liabilities+	17.05M	11.12M	201K	1.21M	7.58M	535K	5.28M	5.57M	2.01M	31K
Long-Term Debt	16.68M	11.01M	0	0	0	0	5M	3.79M	0	0
Capital Lease Obligations	0	0	0	0	646K	528K	269K	141K	85K	31K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	374K	17K	107K	1.04M	6.94M	7K	1K	1.64M	1.92M	0
Total Liabilities	25.49M	23.62M	18.61M	18.77M	22.07M	9.07M	11.14M	17.42M	12.74M	15.58M
Total Debt+	16.68M	17.64M	13.62M	14.2M	11.97M	7M	6.99M	5.75M	4.18M	3.37M
Net Debt	2.34M	5.08M	4.07M	8.94M	-5.58M	-1.35M	-11.41M	-12.37M	-4.37M	3.29M
Debt / Equity	1.37x	1.61x	1.05x	2.72x	10.32x	2.31x	0.65x	0.89x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-4.52x	-7.60x	-10.09x	-4.56x	-1.97x	-8.66x	-13.40x	-27.72x	-33.72x	-3.95x
Total Equity+	12.21M	10.99M	13M	5.22M	1.16M	3.03M	10.84M	6.45M	-1.35M	-8.95M
Equity Growth %	3.14%	-0.1%	0.18%	-0.6%	-0.78%	1.61%	2.58%	-0.41%	-1.21%	-5.64%
Book Value per Share	0.09	0.64	30102.04	450.82	12.57	10.27	13.45	3.68	-0.43	-1.16
Total Shareholders' Equity	12.21M	10.99M	13M	5.22M	1.16M	3.03M	10.84M	6.45M	-1.35M	-8.95M
Common Stock	13K	22K	6K	0	4K	7K	16K	34K	5K	6K
Retained Earnings	-357.02M	-379.06M	-401.75M	-414.38M	-425.27M	-433.51M	-446.91M	-467.19M	-480.5M	-493.48M
Treasury Stock	0	0	0	0	0	0	0	0	-126K	-500K
Accumulated OCI	996K	1.26M	1.39M	1.22M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.47M	-19.53M	-18.13M	-11.97M	-5.91M	-8.43M	-10.28M	-12.97M	-12.85M	-10.55M
Operating CF Margin %	-1.76%	-1.72%	-2.83%	-4.01%	-0.84%	-27.83%	-	-57.91%	-2.62%	-1.81%
Operating CF Growth %	0.33%	0.05%	0.07%	0.34%	0.51%	-0.43%	-0.22%	-0.26%	0.01%	0.18%
Net Income	-18.74M	-22.05M	-22.69M	-12.63M	-10.89M	-8.24M	-13.4M	-20.27M	-13.32M	-12.98M
Depreciation & Amortization	1.09M	1.18M	2.15M	2M	896K	366K	395K	619K	628K	723K
Stock-Based Compensation	2.04M	1.08M	753K	355K	127K	247K	606K	606K	569K	550K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-6.16M	1.02M	2.69M	-668K	4.9M	-925K	880K	481K	384K	-2.07M
Working Capital Changes	1.3M	-772K	-1.04M	-1.03M	-938K	119K	1.24M	5.6M	-1.12M	3.22M
Change in Receivables	328K	-179K	1.13M	-173K	-1.2M	1.17M	0	0	0	-571K
Change in Inventory	490K	471K	251K	475K	259K	0	0	0	0	0
Change in Payables	771K	-673K	-1.82M	-1.42M	-23K	-1.23M	1.73M	0	-3.68M	4.7M
Cash from Investing+	-613K	64K	-1.38M	-133K	5.57M	-493K	-82K	-759K	-160K	-4.11M
Capital Expenditures	-611K	-67K	-1.5M	-133K	-67K	-93K	-144K	-509K	-160K	-146K
CapEx % of Revenue	0.05%	0.01%	0.23%	0.04%	0.01%	0.31%	-	2.27%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2K	131K	113K	0	0	-400K	62K	-250K	0	-545K
Cash from Financing+	20.8M	17.61M	16.82M	7.17M	12.63M	-319K	20.42M	13.45M	3.44M	6.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-75K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-850K	-3.86M	0	-66K	490K	1.1M	2.02M	-773K	-348K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.09M	-19.6M	-19.62M	-12.11M	-5.97M	-8.93M	-10.42M	-13.73M	-13.01M	-10.7M
FCF Margin %	-1.81%	-1.72%	-3.06%	-4.06%	-0.85%	-29.46%	-	-61.3%	-2.65%	-1.84%
FCF Growth %	0.33%	0.07%	-0%	0.38%	0.51%	-0.49%	-0.17%	-0.32%	0.05%	0.18%
FCF per Share	-0.15	-1.13	-45440.19	-1044.69	-64.74	-30.24	-12.93	-7.84	-4.14	-1.39
FCF Conversion (FCF/Net Income)	1.09x	0.89x	0.80x	0.95x	0.54x	1.02x	0.77x	0.64x	0.97x	0.81x
Interest Paid	0	0	0	0	0	0	0	327K	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-576.38%	-190.12%	-189.16%	-138.64%	-341.02%	-393.27%	-193.25%	-234.65%	-522.5%	-
Return on Invested Capital (ROIC)	-116.81%	-96.56%	-93.63%	-42.07%	-56.28%	-	-1688.11%	-	-	-
Gross Margin	72.67%	76.14%	79.44%	61.52%	100%	-791.09%	-	-217.86%	-97.23%	85.37%
Net Margin	-160.77%	-193.73%	-353.86%	-423.53%	-155.57%	-2719.8%	-	-9051.34%	-271.04%	-222.84%
Debt / Equity	1.37x	1.61x	1.05x	2.72x	10.32x	2.31x	0.65x	0.89x	-	-
Interest Coverage	-4.52x	-7.60x	-10.09x	-4.56x	-1.97x	-8.66x	-13.40x	-27.72x	-33.72x	-3.95x
FCF Conversion	1.09x	0.89x	0.80x	0.95x	0.54x	1.02x	0.77x	0.64x	0.97x	0.81x
Revenue Growth	53.45%	-2.39%	-43.66%	-53.47%	134.6%	-95.67%	-100%	-	2093.3%	18.54%

Revenue by Segment

	2012	2013	2014	2015	2016	2017	2018	2019	2022
Grant	-	-	-	-	-	-	-	-	224K
Grant Growth	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	-	2.67M	901K	-
Product Growth	-	-	-	-	-	-	-	-66.27%	-
Consumable	-	-	-	-	-	-	2.17M	-	-
Consumable Growth	-	-	-	-	-	-	-	-	-
Other Products	-	-	-	-	-	-	277K	-	-
Other Products Growth	-	-	-	-	-	-	-	-	-
Device	-	-	-	-	-	-	225K	-	-
Device Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2012	2013	2014	2015	2016	2017	2018	2019	2022
JAPAN	-	-	-	2.39M	3.28M	1.92M	2.06M	-	-
JAPAN Growth	-	-	-	-	36.97%	-41.32%	6.96%	-	-
Americas	-	-	-	-	936K	345K	293K	-	-
Americas Growth	-	-	-	-	-	-63.14%	-15.07%	-	-
E M E A	-	-	-	-	379K	344K	270K	-	-
E M E A Growth	-	-	-	-	-	-9.23%	-21.51%	-	-
Asia Pacific	-	-	-	787K	62K	76K	50K	-	-
Asia Pacific Growth	-	-	-	-	-92.12%	22.58%	-34.21%	-	-
America	-	-	-	982K	-	-	-	-	-
America Growth	-	-	-	-	-	-	-	-	-
Europe	2M	1.24M	506K	675K	-	-	-	-	-
Europe Growth	-	-38.12%	-59.19%	33.40%	-	-	-	-	-
Japan	-	-	3.07M	-	-	-	-	-	-
Japan Growth	-	-	-	-	-	-	-	-	-
North America	1.14M	1.08M	894K	-	-	-	-	-	-
North America Growth	-	-5.60%	-17.15%	-	-	-	-	-	-
Other countries	1.21M	2.69M	485K	-	-	-	-	-	-
Other countries Growth	-	122.64%	-82.00%	-	-	-	-	-	-
Japan segment	4.35M	2.11M	-	-	-	-	-	-	-
Japan segment Growth	-	-51.54%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Plus Therapeutics, Inc. (PSTV) reported $5.3M in revenue for fiscal year 2024. This represents a 47% decrease from $10.0M in 2011.

Plus Therapeutics, Inc. (PSTV) grew revenue by 18.5% over the past year. This is strong growth.

Plus Therapeutics, Inc. (PSTV) reported a net loss of $20.6M for fiscal year 2024.

Dividend & Returns

Plus Therapeutics, Inc. (PSTV) had negative free cash flow of $15.8M in fiscal year 2024, likely due to heavy capital investments.